Cavalier Jason 4
4 · Lyra Therapeutics, Inc. · Filed Jan 8, 2026
Insider Transaction Report
Form 4
Cavalier Jason
Chief Financial Officer
Transactions
- Sale
Common Stock
2026-01-06$3.36/sh−769$2,587→ 518,547 total
Footnotes (1)
- [F1]Shares were sold to cover taxes upon the vesting of restricted stock units ("RSUs") pursuant to a mandatory Rule 10b5-1 trading instruction in the award agreement adopted by the Reporting Person on January 1, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.